Not a dead duck

Kazia Posts Interim Data From Paxalisib Combo Study In Brain Metastases

Kazia Therapeutics Limited

KZIA+4.79%+ Free Alerts
announced the presentation of new data from an ongoing phase 1 trial of paxalisib in combination with radiotherapy for brain metastases.
Interim data from the first stage of the study reports that all nine evaluable patients experienced a complete or partial response, representing an overall response rate (ORR) of 100%.
The safety profile of paxalisib in combination was broadly consistent with monotherapy experience in other clinical trials. A maximum tolerated dose (MTD) of 45mg daily combined with radiotherapy was confirmed.
Shares are up 31.8% at $2.34 during the market session.